Academic Journals Database
Disseminating quality controlled scientific knowledge

Adjuvant Radiotherapy and Chemotherapy for Resected Pancreatic Adenocarcinoma: Review of Current Evidence

ADD TO MY LIST
 
Author(s): Michelle A Neben-Wittich | Michael C Stauder | Fernando Quevedo | Michele M Corsini | Matthew J Iott | Robert C Miller

Journal: European Journal of Clinical & Medical Oncology
ISSN 1759-8958

Volume: 2;
Issue: 1;
Start page: 89;
Date: 2010;
VIEW PDF   PDF DOWNLOAD PDF   Download PDF Original page

Keywords: pancreas | adenocarcinoma | adjuvant | chemotherapy | chemoradiation | radiotherapy | surgery

ABSTRACT
Pancreatic adenocarcinoma is an aggressive cancer with an overall 5-year survival of 5% or less. In patients who have resectable tumors, resection can lead to an improvement in overall survival, but local and distant recurrence rates remain high. Adjuvant therapy has demonstrated mixed results in clinical trials; thus the optimal adjuvant treatment of resected pancreatic cancer remains unclear. The purpose of this article is to review and assess the pertinent literature and try to determine an acceptable and uniform approach to adjuvant therapy in patients with resected adenocarcinoma of the pancreas. We focus on adjuvant chemotherapy and chemoradiation, and their impact on overall survival in this subgroup of patients.
RPA Switzerland

RPA Switzerland

Robotic process automation

    

Tango Jona
Tangokurs Rapperswil-Jona